Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36‐month clinical trial
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background: The effects of pioglitazone on bone metabolism are unclear. This study evaluated the long‐term effects of pioglitazone on bone mineral density (BMD) and bone metabolism in patients with prediabetes or type 2 diabetes mellitus (T2DM) and non‐alcoholic steatohepatitis (NASH). Methods: Ninety‐two patients with prediabetes or T2DM and biopsy‐proven NASH with BMD and baseline biochemical bone measurements were included. Patients (mean [±SEM] age 51 ± 1 years, 71% male, mean body mass index 34.5 ± 0.5 kg/m 2) were randomly assigned to pioglitazone (45 mg/day) or placebo for 18 months, followed by an 18‐month open‐label pioglitazone treatment phase. Baseline, 18‐ and 36‐month evaluations included plasma vitamin D and bone turnover biomarker levels, and BMD measurements at the spine, femoral neck, total hip, and one‐third radius. Results: After 18 months of pioglitazone treatment, there were no differences in BMD versus placebo at either the femoral neck (P =0.87), total hip (P =0.78), or one‐third radius (P =0.44); however, bone density decreased at the level of the spine with pioglitazone (−3.5%; P =0.002). During the extension phase (18–36 months), patients had no further decreases in BMD or plasma biomarkers of bone turnover during pioglitazone treatment. No patient experienced a low‐energy bone fracture. Conclusions: Treatment of patients with prediabetes or T2DM with pioglitazone for up to 3 years was associated with decreased BMD at the level of the lumbar spine. This reduction in BMD at the lumbar spine at 18 months versus placebo suggests an early deleterious effect of pioglitazone on bone metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Self-citationMechanisms of diabetes mellitus-induced bone fragility
On behalf of the IOF Bone and Diabetes Working Group, Napoli, N., Chandran, M., Pierroz, D. D., Abrahamsen, B., Schwartz, A. V., & Ferrari, S. L. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.153 · Cited by 1,107 · cited 1×
“The mechanisms by which TZDs can potentially influence bone turnover remain controversial.(3,6) Insulin resistance in obesity or uncontrolled diabetes have been proposed as a mechanism for bone loss given the role of insulin signaling in bone homeostasis.”
BackgroundCusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024 · cited 9×
“Patients treated for 36 months maintained good glycemic control and improved insulin sensitivity, as reported elsewhere.(10) The effect of pioglitazone at different skeletal sites (lumbar spine, hip, and femoral neck) is shown in Fig.”
BackgroundMethodInfluentialSelf-citationPioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721 · cited 1×
“No increase in fractures has been reported in RCTs in patients with biopsy-proven NASH treated with pioglitazone for ≤2 years.(9,25,26) The present study is the first to report serial BMD measurements and plasma bone biomarkers in patients with NASH over a more extended period of time (3 years).”
BackgroundRosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes
Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.005 · Cited by 518
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503 · cited 3×
“Patients with T2DM are often obese, which further complicates the matter because obesity leads to increased bone mineral density (BMD) but an underestimation about an individual’s true fracture risk reported.1–3 Treatment of T2DM with pioglitazone is associated with broad effects not only on glucose and lipid metaboli…”
BackgroundSelf-citationRisk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhu, Z.-N., Jiang, Y.-F., & Ding, T. (2014) · Bone · doi:10.1016/j.bone.2014.08.010 · Cited by 253 · cited 3×
“001) and a greater effect in women exposed for >2 years.(12) No increase in fractures has been reported in RCTs in patients with biopsy-proven NASH treated with pioglitazone for ≤2 years.”
BackgroundResultInfluentialBillington, E. O., Grey, A., & Bolland, M. J. (2015) · Diabetologia · doi:10.1007/s00125-015-3660-2 · Cited by 133
Cited by
Eslam, M., Sarin, S. K., Wong, V. W.-S., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M.-H., Shiha, G., Yilmaz, Y., Gani, R., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 833
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Self-citationNonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
Self-citationBreakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Ipsen, E. Ø., Madsen, K. S., Chi, Y., Pedersen-Bjergaard, U., Richter, B., Metzendorf, M.-I., & Hemmingsen, B. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013516.pub2 · Cited by 23
Metadata
- Authors
- Portillo‐Sanchez, P., Bril, F., Lomonaco, R., Barb, D., Orsak, B., Bruder, J. M., & Cusi, K.
- Venue
- Journal of Diabetes
- Publisher
- Wiley
- Published
- 2018-09-03
- Volume
- 11
- Issue
- 3
- Pages
- 223-231
- ISSN
- 1753-0393 (ISSN-L)
- 1753-0407
- OpenAlex
- W2887038895
- Cited by
- 43
- References
- 14
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36‐month clinical trial. https://app.cochat.ai/papers/10.1111/1753-0407.12833
- The paper
- Portillo‐Sanchez, P., Bril, F., Lomonaco, R., Barb, D., Orsak, B., Bruder, J. M., & Cusi, K. (2019). Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36‐month clinical trial. Journal of Diabetes. https://doi.org/10.1111/1753-0407.12833
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.